Vaginal Estrogen Therapy Doesn’t Raise Recurrence Risk in Endometrial Cancer Survivors | Healio Endocrinology News

For women who have survived endometrial cancer, maintaining vaginal health without increasing the risk of cancer returning has been a significant concern. Recent research published in Menopause offers reassuring news: vaginal estrogen therapy does not appear to elevate the risk of endometrial cancer recurrence. This finding could lead to more open discussions between clinicians and patients about managing the genitourinary symptoms that often accompany cancer treatment and menopause, improving quality of life for survivors.

Understanding the Study and Its Implications

The retrospective cohort study, led by Christine D. Hsu, PharmD, PhD, of the University of Texas Medical Branch in Galveston, analyzed data from the TriNetX U.S. Collaborative Network, encompassing over 25,000 women diagnosed with endometrial cancer between November 2005 and December 2023. Researchers focused on identifying whether the use of vaginal estrogen therapy after an initial diagnosis impacted the rate of cancer recurrence within 1 to 6 years. The study meticulously matched 1,412 women who used vaginal estrogen with a comparable group who did not, using propensity score matching to account for potential biases.

The results showed no statistically significant difference in recurrence rates between the two groups – 53 recurrences in the vaginal estrogen group versus 54 in the non-user group. This suggests that, for endometrial cancer survivors, vaginal estrogen therapy doesn’t carry an increased risk of the cancer returning. Dr. Hsu emphasized that this is, to their knowledge, the largest U.S. Study to examine this specific relationship, utilizing a substantial dataset and a relatively long follow-up period (over four years for both groups).

Addressing Genitourinary Symptoms in Cancer Survivors

Endometrial cancer treatment, including surgery, chemotherapy, and radiation, can often lead to a decline in estrogen levels, causing genitourinary symptoms like vaginal dryness, itching, and painful intercourse. These symptoms can significantly impact a woman’s quality of life. Monica Christmas, MD, FACOG, MSCP, associate medical director for The Menopause Society, highlighted this issue in a press release, noting that these symptoms rarely improve without intervention and are often worsened by the abrupt menopause experienced by many cancer survivors.

The study’s findings are particularly timely given the recent changes to the FDA’s black box warning for menopausal hormone therapies. These changes aim to provide a more nuanced understanding of the risks and benefits of hormone therapy, potentially encouraging more informed discussions between patients and healthcare providers.

What the Study Doesn’t Inform Us

While the study provides encouraging data, it’s crucial to understand its limitations. As a retrospective cohort study, it can demonstrate association but not causation. It’s possible that other factors, not accounted for in the analysis, could influence both the use of vaginal estrogen and the risk of cancer recurrence. The researchers acknowledged this, and used influenza vaccination as a negative control to attempt to mitigate potential biases.

the study focused on a specific population – women diagnosed with endometrial cancer. The findings may not be generalizable to women with other types of cancer or to different populations. The study similarly did not delve into the specific types or dosages of vaginal estrogen used, which could potentially influence outcomes.

Understanding Propensity Score Matching

Propensity score matching is a statistical technique used to reduce bias in observational studies. Because the study wasn’t a randomized controlled trial, researchers couldn’t randomly assign women to receive or not receive vaginal estrogen. Instead, they used propensity score matching to create two groups – users and non-users – that were as similar as possible in terms of other characteristics that could influence cancer recurrence, such as age, stage of cancer, and other health conditions. This helps to strengthen the validity of the study’s findings, but it doesn’t eliminate all potential sources of bias.

The Role of Shared Decision-Making

The study underscores the importance of shared decision-making between clinicians and patients. Women who have survived endometrial cancer and are experiencing genitourinary symptoms should discuss the potential benefits and risks of vaginal estrogen therapy with their healthcare provider. This discussion should consider individual risk factors, treatment history, and personal preferences.

Dr. Christmas emphasized that empowering survivors of endometrial cancer to make evidence-based decisions about their care is crucial, particularly during a vulnerable time. Expanding treatment options to include local, low-dose vaginal estrogen therapy could offer significant benefits for many women.

Future Research Directions

Dr. Hsu and her team suggest that future research should focus on understanding how many endometrial cancer survivors initiate vaginal estrogen therapy in light of the recent FDA changes to hormone therapy warnings. Further studies are also needed to identify factors that contribute to treatment initiation and discontinuation, including barriers to care, treatment costs, and potential adverse effects.

Researchers should also investigate the optimal dosage and duration of vaginal estrogen therapy for endometrial cancer survivors, as well as the potential impact of different formulations. Longer-term follow-up studies are needed to assess the long-term effects of vaginal estrogen therapy on cancer recurrence and overall survival.

For more information:

Christine D. Hsu, PharmD, PhD, can be reached at [email protected].